Notably, enhancing of hemorrhagic stroke complication by anticoagulation and antiplatelet drugs seems to rely partially on MMP-9 activation or inhibition, since in experimental studies, implementing animal models of stroke and recanalization, administration of dabigatran or rivaroxaban and apixaban demonstrated its superiority over warfarin therapy as to the risk of secondary hemorrhage in relation with decreased MMP-9 activation after stroke and reperfusion [187,188,189,190]. The gene discussed is MMP9; the disease is hemorrhagic stroke.